Cargando…

Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma

Long-term kinetics of antibody (Ab) and cell-mediated immune (CMI) response to full anti-SARS-CoV-2 vaccine schedule and booster doses in Multiple Myeloma (MM) patients remain unclear. We prospectively evaluated Ab and CMI response to mRNA vaccines in 103 SARS-CoV-2-naïve MM patients (median age 66,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mancuso, Katia, Zamagni, Elena, Solli, Vincenza, Gabrielli, Liliana, Leone, Marta, Pantani, Lucia, Rocchi, Serena, Rizzello, Ilaria, Tacchetti, Paola, Ghibellini, Stefano, Favero, Emanuele, Ursi, Margherita, Talarico, Marco, Barbato, Simona, Kanapari, Ajsi, Bigi, Flavia, Puppi, Michele, Terragna, Carolina, Borsi, Enrica, Martello, Marina, Poletti, Andrea, Scatà, Alessandra, Nepoti, Giuliana, Ruffini, Barbara, Lazzarotto, Tiziana, Cavo, Michele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249866/ https://www.ncbi.nlm.nih.gov/pubmed/37305577 http://dx.doi.org/10.3389/fonc.2023.1208741

Ejemplares similares

Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients
por: Martello, Marina, et al.
Publicado: (2022)

High Humoral Response after Anti-Sars-Cov-2 mRNA-Based Vaccines in Patients with Active Multiple Myeloma (MM) and Relationship with Disease Status/Line of Therapy
por: Mancuso, Katia, et al.
Publicado: (2021)

P860: CIRCULATING MULTIPLE MYELOMA CELLS (CMMCS) AS PROGNOSTIC FACTOR AND MINIMAL RESIDUAL DISEASE MARKER IN MM AND SMOULDERING MM PATIENTS
por: Vigliotta, Ilaria, et al.
Publicado: (2023)

Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma
por: Martello, M., et al.
Publicado: (2022)

Role of serum‐free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma
por: Tacchetti, Paola, et al.
Publicado: (2022)

The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases
por: Vigliotta, Ilaria, et al.
Publicado: (2022)

BoBafit: A copy number clustering tool designed to refit and recalibrate the baseline region of tumors’ profiles
por: Mazzocchetti, G., et al.
Publicado: (2022)

Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma Patients
por: Zamagni, Elena, et al.
Publicado: (2020)

Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma
por: Borsi, Enrica, et al.
Publicado: (2014)

Front-line treatment of multiple myeloma
por: Cavo, Michele, et al.
Publicado: (2019)

The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)
por: Terragna, Carolina, et al.
Publicado: (2015)

Cap dependent translation contributes to resistance of myeloma cells to bortezomib
por: Mancino, Marilena, et al.
Publicado: (2013)

Early Light Chains Removal and Albumin Levels with a Double Filter-Based Extracorporeal Treatment for Acute Myeloma Kidney
por: Donati, Gabriele, et al.
Publicado: (2022)

P64 A CASE OF COVID-19 PNEUMONIA AFTER CAR T-CELL THERAPY IN A PATIENT AFFECTED BY RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Ielo, C., et al.
Publicado: (2023)

Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma
por: Bonello, Francesca, et al.
Publicado: (2022)

Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche
por: Solimando, Antonio Giovanni, et al.
Publicado: (2022)

Inverse probability weighting to estimate causal effect of a singular phase in a multiphase randomized clinical trial for multiple myeloma
por: Pezzi, Annalisa, et al.
Publicado: (2016)

Disease-Specific Derangement of Circulating Endocannabinoids and N-Acylethanolamines in Myeloproliferative Neoplasms
por: Forte, Dorian, et al.
Publicado: (2020)

(11)C-choline vs. (18)F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma
por: Nanni, Cristina, et al.
Publicado: (2007)

The Role of Monoclonal Antibodies in Smoldering and Newly Diagnosed Transplant-Eligible Multiple Myeloma
por: Zamagni, Elena, et al.
Publicado: (2020)

Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time?
por: Bolli, Niccolo, et al.
Publicado: (2020)

The hypnagogic state: A brief update
por: Ghibellini, Romain, et al.
Publicado: (2022)

Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives
por: Romano, Alessandra, et al.
Publicado: (2019)

Unraveling the Role of Peroxisome Proliferator-Activated Receptor β/Δ (PPAR β/Δ) in Angiogenesis Associated with Multiple Myeloma
por: Leone, Patrizia, et al.
Publicado: (2023)

Diagnosis and Treatment of VOD/SOS After Allogeneic Hematopoietic Stem Cell Transplantation
por: Bonifazi, Francesca, et al.
Publicado: (2020)

CAR T-cell therapy for triple-class exposed relapsed/refractory multiple myeloma
por: Cavo, Michele
Publicado: (2023)

Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials
por: Morabito, Fortunato, et al.
Publicado: (2022)

Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity
por: Auteri, Giuseppe, et al.
Publicado: (2022)

New Insights into the Significance of PARP-1 Activation: Flow Cytometric Detection of Poly(ADP-Ribose) as a Marker of Bovine Intramammary Infection
por: De Matteis, Giovanna, et al.
Publicado: (2021)

Implementation and tuning of the Extended Kalman Filter for a sensorless drive working with arbitrary stepper motors and cable lengths
por: Butcher, Mark, et al.
Publicado: (2018)

Targeting the Endothelin-1 Receptors Curtails Tumor Growth and Angiogenesis in Multiple Myeloma
por: Russignan, Anna, et al.
Publicado: (2021)

Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell’Adulto Multiple Myeloma Working Party study
por: Musto, Pellegrino, et al.
Publicado: (2015)

Hey teachers! Do not leave them kids alone! Envisioning schools during and after the coronavirus (COVID-19) pandemic
por: Poletti, Michele
Publicado: (2020)

Covid 19 - some Lessons from Public Administrations for Humanistic Management
por: Ruffini, Renato, et al.
Publicado: (2022)

Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial
por: Zamagni, Elena, et al.
Publicado: (2023)

Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug Resistant Pseudomonas aeruginosa Infections in Neutropenic Patients
por: Coppola, Paolo E., et al.
Publicado: (2020)

The Power of Extracellular Vesicles in Myeloproliferative Neoplasms: “Crafting” a Microenvironment That Matters
por: Catani, Lucia, et al.
Publicado: (2021)

A prospective observational study to assess clinical decision-making, prognosis, quality of life and satisfaction with care in patients with relapsed/refractory multiple myeloma: the CLARITY study protocol
por: Efficace, Fabio, et al.
Publicado: (2018)

The Role of Mesenchymal Stem Cells in Radiation-Induced Lung Fibrosis
por: Zanoni, Michele, et al.
Publicado: (2019)

Non-nuclear AR Signaling in Prostate Cancer
por: Zamagni, Alice, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rmc9o4n0bi7viabb89l1b6841n